

CEAPRO INC. develops and uses proprietary extraction technology to produce active ingredients from renewable plant resources. Nature's vitality underlies all of Ceapro's products as the Company fosters natural and sustainable plant materials. We provide "green" and innovative functional ingredients to manufacturers of personal care products, nutraceuticals and developers of therapeutics.



JUNE 2009



Innovative Technology

Intellectual Capital



We have a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and medical sciences. These skills merge in the fields of active ingredients, bio pharmaceuticals and drug-delivery solutions.

Our Patent Portfolio includes:

- Process patents to protect extraction and standardization of our products;
- Patents protecting the composition and use of our active ingredients for the cosmeceutical and nutraceutical markets.

PRODUCTS

Our current range of 11 products are essential ingredients for leading skin care, makeup, hair care, fragrances, oral care, and other toiletry products from leading brands such as Aveeno®, Neutrogena®, Dove®, Burt's Bees®, Avalon Organics® and Glucan Pro®.

Avenanthramides

Ceapro holds the only patents for the extraction and concentration of avenanthramides from oats. Avenanthramides are oat-derived compounds that Ceapro has made functional for use in therapeutics for skin allergies and inflammation. Potential medical applications include inflammatory bowel disease and atherosclerosis.

Beta glucan

Ceapro has become a recognized leader in the science and function of beta glucan. Our beta glucan extracts are distinguished from other sources extracts and have better purity characteristics by virtue of its patented biotechnology process at the nano molecular scale level. We were the first to demonstrate that beta glucan can penetrate human skin.



Rosmarinic acid


Ceapro has licensed exclusive rights of a unique spearmint variety containing very high levels of rosmarinic acid, a powerful antioxidant and anti-inflammatory. The appeal for Ceapro is threefold:

- Mint is a natural ingredient, fitting in well with Ceapro's production of active ingredients and products.
- It is a hearty and fecund plant, making it a cost-effective source of rosmarinic acid.
- Rosmarinic acid can be colourless and flavourless, making it a superlative active ingredient for inclusion in cosmeceuticals and nutraceuticals.

GLOBAL PARTNERSHIPS

To introduce, promote, and sell our products, we create partnerships with the world's leading marketing companies. Our innovative technology is a powerful enabler and adds value to products in the cosmetics, personal care, nutraceutical and pharmaceutical sectors.

We work with well-connected, experienced partners. Their global sales forces give us access to large clients such as Johnson & Johnson, L'Oréal, Estée Lauder and Chanel.



Growth Prospects

Currently targeted by Ceapro, the cosmeceutical market, valued at \$50 billion, is fast-growing and propelled by streams of new products offering age-defying benefits, aging populations in developed countries and increased income in some emerging countries.

In the coming years, Ceapro plans to enter the nutraceutical market and enhance its own strategic alliances with large pharmaceutical groups.

The nutraceutical market is considered to be four times more important than cosmeceuticals, while the pharmaceutical market is estimated at \$400 billion.

Management

Acting CEO Gilles Gagnon, M.Sc., MBA, has 25 years of experience in healthcare and pharmaceutical organizations namely as CEO of Æterna Zentaris, VP External Affairs at Novartis Pharmaceuticals and Executive Director at Sandoz Canada.

CFO & VP Finance Branko Jankovic, B.Comm., has 20 years of finance and business experience.

CSO David Fielder, M.Sc., has 20 years of experience in scientific research and commercial experience of plant extracts and has been with Ceapro since its foundation, after seven years with Agriculture & Agri-Food Canada.

Investment Highlights

- Strong portfolio of commercialized innovative products
- Development of new products for nutraceutical and therapeutic markets
- Strong distribution partnerships worldwide
- Strong Management well connected and knowledgeable of growth opportunities

Stock Information - June 2009

Symbol: CZO on the Venture Stock Exchange
52 week trading range: \$0.02 – \$0.20
Shares outstanding: 47 million
Market Capitalization: \$3 million
Year founded: 1997
Number of employees: 23
Revenue estimate for 2009: \$6 to 7 million

Investor Relations

SUN INTERNATIONAL COMMUNICATIONS

Nicole Blanchard B.Sc.

T 450.973.6600

E nicole.blanchard@isuncomm.com



Suite 4174 Enterprise Square
10230 Jasper Avenue NW
Edmonton, Alberta T5J 4P6
T 780.421.4555
F 780.421.1320
www.ceapro.com

FORWARD-LOOKING STATEMENTS - Certain "forward-looking statements" contained in this fact sheet may involve a number of risks and uncertainties. There can be no assurance that these statements will prove to be correct, and actual results and future events could differ considerably from those implied by such statements. All essential information and press releases to complement this factsheet can be found on www.ceapro.com.